Wu D, Jansen-van Vuuren RD, Dasgupta A, Al-Qazazi R, Chen KH, Martin AY, Mewburn JD, Alizadeh E, Lima PDA, Jones O, Colpman P, Bentley RET, VandenBroek MM, Breault NM, Emon IM, Yerramilli VS, Jedlovcnik L, Zhao YY, Wells M, Sutendra G, Ormiston ML and Archer SL. Novel Drp1 GTPase Inhibitor, Drpitor1a: Efficacy in Pulmonary Hypertension. Hypertension. 2024;81:2189–2201.
Zhang ZJ, Wang HF, Lian TY, Zhou YP, Xu XQ, Guo F, Wei YP, Li JY, Sun K, Liu C, Pan LR, Ren M, Nie L, Dai HL and Jing ZC. Human Plasma IgG N-Glycome Profiles Reveal a Proinflammatory Phenotype in Chronic Thromboembolic Pulmonary Hypertension. Hypertension. 2023;80:1929–1939.
Razee A, Banerjee S, Hong J, Magaki S, Fishbein G, Ajijola OA and Umar S. Thoracic Spinal Cord Neuroinflammation as a Novel Therapeutic Target in Pulmonary Hypertension. Hypertension. 2023;80:1297–1310.
Hilton LR, Ratsep MT, VandenBroek MM, Jafri S, Laverty KJ, Mitchell M, Theilmann AL, Smart JA, Hawke LG, Moore SD, Renaud SJ, Soares MJ, Morrell NW and Ormiston ML. Impaired Interleukin-15 Signaling via BMPR2 Loss Drives Natural Killer Cell Deficiency and Pulmonary Hypertension. Hypertension. 2022;79:2493–2504.
Zhang MQ, Wang CC, Pang XB, Shi JZ, Li HR, Xie XM, Wang Z, Zhang HD, Zhou YF, Chen JW, Han ZY, Zhao LL and He YY. Role of macrophages in pulmonary arterial hypertension. Front Immunol. 2023;14:1152881.